

**FACSIMILE TRANSMITTAL SHEET AND  
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

**RECEIVED  
CENTRAL FAX CENTER**

**FEB 13 2006**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied documents to us.

**TO: U.S. Patent Office  
Central Facsimile  
Processing Facility  
Mail Stop AF**

**FROM: Daniel F. Nesbitt  
Hasse & Nesbitt LLC**

**PHONE: (571) 272-4000**

**PHONE: (513) 229-0383**

**FAX: (571) 273-8300**

**FAX: (513) 229-0683**

\*\*\*\*\*

**I, Elaine Willig, hereby certify that the below identified  
correspondence is being facsimile transmitted to the United  
States Patent and Trademark Office on February 13, 2006.**

**Signature: Elaine Willig**

\*\*\*\*\*

**Pages being transmitted:**

**Total No. of Pages including this cover letter: 8**

**1. Amendment after Final (7 pages).**

**Application No.: 10/724,532**

**Filed: 11/29/2003**

**Inventor: Reed**

**Attorney Docket No.: GMX-002**

**COMMENTS:**

Attorney Docket No. GMX-002

RECEIVED  
CENTRAL FAX CENTER

FEB 13 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Reed, Thomas D. : Examiner: Karen Cochrane Carlson  
Serial No: 10/724,532 : Group Art Unit: 1653  
Filed: November 29, 2003 : Confirmation No: 3265  
Title: SIGNAL FOR TARGETING MOLECULES TO THE  
SARCO(ENDO)PLASMIC RETICULUM

**AMENDMENT AFTER FINAL OFFICE ACTION PURSUANT TO 37 C.F.R. 1.116**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated December 14, 2005, please enter the following amendments and consider the accompanying remarks.

**Amendments to the Claims** are reflected in the listing of claims that begin on page 2 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.